195 related articles for article (PubMed ID: 33021466)
1. Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECOURSE trial.
Pietrantonio F; Fucà G; Manca P; Pagani F; Raimondi A; Prisciandaro M; Randon G; Corti F; de Braud F; Cremolini C; Miceli R
Tumori; 2021 Aug; 107(4):353-359. PubMed ID: 33021466
[TBL] [Abstract][Full Text] [Related]
2. A systematic review of observational studies of trifluridine/tipiracil (TAS-102) for metastatic colorectal cancer.
Andersen SE; Andersen IB; Jensen BV; Pfeiffer P; Ota T; Larsen JS
Acta Oncol; 2019 Aug; 58(8):1149-1157. PubMed ID: 31002008
[No Abstract] [Full Text] [Related]
3. Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram.
Pietrantonio F; Miceli R; Rimassa L; Lonardi S; Aprile G; Mennitto A; Marmorino F; Bozzarelli S; Antonuzzo L; Tamburini E; Morano F; Rossini D; Battaglin F; Baretti M; Berenato R; Formica V; Mosconi S; Petrelli F; Ghidini M; Loupakis F; Spada D; Cinieri S; Beretta G; Falcone A; de Braud F; Cremolini C
Ann Oncol; 2017 Mar; 28(3):555-561. PubMed ID: 27864220
[TBL] [Abstract][Full Text] [Related]
4. Relationship Between Thymidine Kinase 1 Expression and Trifluridine/Tipiracil Therapy in Refractory Metastatic Colorectal Cancer: A Pooled Analysis of 2 Randomized Clinical Trials.
Yoshino T; Yamazaki K; Shinozaki E; Komatsu Y; Nishina T; Baba H; Tsuji A; Tsuji Y; Yamaguchi K; Sugimoto N; Denda T; Muro K; Takayama T; Esaki T; Hamamoto Y; Moriwaki T; Shimada Y; Goto M; Nakayama N; Fujii H; Tanase T; Ohtsu A
Clin Colorectal Cancer; 2018 Dec; 17(4):e719-e732. PubMed ID: 30172759
[TBL] [Abstract][Full Text] [Related]
5. Trifluridine/Tipiracil (TAS-102) in Refractory Metastatic Colorectal Cancer: A Multicenter Register in the Frame of the Italian Compassionate Use Program.
Cremolini C; Rossini D; Martinelli E; Pietrantonio F; Lonardi S; Noventa S; Tamburini E; Frassineti GL; Mosconi S; Nichetti F; Murgioni S; Troiani T; Borelli B; Zucchelli G; Dal Maso A; Sforza V; Masi G; Antoniotti C; Di Bartolomeo M; Miceli R; Ciardiello F; Falcone A
Oncologist; 2018 Oct; 23(10):1178-1187. PubMed ID: 29739893
[TBL] [Abstract][Full Text] [Related]
6. Safety of trifluridine/tipiracil in an open-label expanded-access program in elderly and younger patients with metastatic colorectal cancer.
Mayer RJ; Hochster HS; Cohen SJ; Winkler R; Makris L; Grothey A
Cancer Chemother Pharmacol; 2018 Dec; 82(6):961-969. PubMed ID: 30350179
[TBL] [Abstract][Full Text] [Related]
7. Neutropenia is an indicator of outcomes in metastatic colorectal cancer patients treated with FTD/TPI plus bevacizumab: a retrospective study.
Nose Y; Kagawa Y; Hata T; Mori R; Kawai K; Naito A; Sakamoto T; Murakami K; Katsura Y; Ohmura Y; Masuzawa T; Takeno A; Takeda Y; Kato T; Murata K
Cancer Chemother Pharmacol; 2020 Sep; 86(3):427-433. PubMed ID: 32816155
[TBL] [Abstract][Full Text] [Related]
8. Prediction of survival in patients with advanced, refractory colorectal cancer in treatment with trifluridine/tipiracil: real-world vs clinical trial data.
Fernández Montes A; Carmona-Bayonas A; Jimenez-Fonseca P; Vázquez Rivera F; Martinez Lago N; Covela Rúa M; Cousillas Castiñeiras A; Gonzalez Villarroel P; De la Cámara Gómez J; Méndez JCM; Carriles Fernández C; Sanchez Cánovas M; Garcia García T
Sci Rep; 2021 Jul; 11(1):14321. PubMed ID: 34253805
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/Tipiracil and Regorafenib in Patients with Metastatic Colorectal Cancer: A Retrospective Study at a Tertiary Oncology Center.
Patel AK; Abhyankar R; Brais LK; Duh MS; Barghout VE; Huynh L; Yenikomshian MA; Ng K; Fuchs CS
Oncologist; 2021 Dec; 26(12):e2161-e2169. PubMed ID: 34406678
[TBL] [Abstract][Full Text] [Related]
10. Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study.
Moriwaki T; Fukuoka S; Taniguchi H; Takashima A; Kumekawa Y; Kajiwara T; Yamazaki K; Esaki T; Makiyama C; Denda T; Satake H; Suto T; Sugimoto N; Enomoto M; Ishikawa T; Kashiwada T; Sugiyama M; Komatsu Y; Okuyama H; Baba E; Sakai D; Watanabe T; Tamura T; Yamashita K; Gosho M; Shimada Y
Oncologist; 2018 Jan; 23(1):7-15. PubMed ID: 28894015
[TBL] [Abstract][Full Text] [Related]
11. Neutropenia and survival outcomes in metastatic colorectal cancer patients treated with trifluridine/tipiracil in the RECOURSE and J003 trials.
Yoshino T; Cleary JM; Van Cutsem E; Mayer RJ; Ohtsu A; Shinozaki E; Falcone A; Yamazaki K; Nishina T; Garcia-Carbonero R; Komatsu Y; Baba H; Argilés G; Tsuji A; Sobrero A; Yamaguchi K; Peeters M; Muro K; Zaniboni A; Sugimoto N; Shimada Y; Tsuji Y; Hochster HS; Moriwaki T; Tran B; Esaki T; Hamada C; Tanase T; Benedetti F; Makris L; Yamashita F; Lenz HJ
Ann Oncol; 2020 Jan; 31(1):88-95. PubMed ID: 31912801
[TBL] [Abstract][Full Text] [Related]
12. Trifluridine/tipiracil plus bevacizumab for third-line management of metastatic colorectal cancer: SUNLIGHT study design.
Tabernero J; Taieb J; Prager GW; Ciardiello F; Fakih M; Leger C; Fougeray R; Amellal N; van Cutsem E
Future Oncol; 2021 Jun; 17(16):1977-1985. PubMed ID: 33569986
[TBL] [Abstract][Full Text] [Related]
13. The subgroups of the phase III RECOURSE trial of trifluridine/tipiracil (TAS-102) versus placebo with best supportive care in patients with metastatic colorectal cancer.
Van Cutsem E; Mayer RJ; Laurent S; Winkler R; Grávalos C; Benavides M; Longo-Munoz F; Portales F; Ciardiello F; Siena S; Yamaguchi K; Muro K; Denda T; Tsuji Y; Makris L; Loehrer P; Lenz HJ; Ohtsu A;
Eur J Cancer; 2018 Feb; 90():63-72. PubMed ID: 29274618
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of trifluridine and tipiracil (TAS-102) versus placebo, with supportive care, in a randomized, controlled trial of patients with metastatic colorectal cancer from Spain: results of a subgroup analysis of the phase 3 RECOURSE trial.
Longo-Muñoz F; Argiles G; Tabernero J; Cervantes A; Gravalos C; Pericay C; Gil-Calle S; Mizuguchi H; Carrato-Mena A; Limón ML; Garcia-Carbonero R
Clin Transl Oncol; 2017 Feb; 19(2):227-235. PubMed ID: 27443414
[TBL] [Abstract][Full Text] [Related]
15. RETRO-TAS, a Retrospective Observational Study of Trifluridine/Tipiracil in Chemorefractory Metastatic Colorectal Cancer.
Koumarianou A; Ntavatzikos A; Symeonidis D; Vallilas C; Giannakakou M; Papaxoinis G; Xynogalos S; Boukovinas I; Demiri S; Kampoli K; Oikonomopoulos G; Samantas E; Res E; Androulakis N; Vourli G; Souglakos I; Karamouzis M
Biomedicines; 2023 Apr; 11(5):. PubMed ID: 37238938
[TBL] [Abstract][Full Text] [Related]
16. Metastatic Colorectal Carcinoma after Second Progression and the Role of Trifluridine-Tipiracil (TAS-102) in Switzerland.
Siebenhüner A; De Dosso S; Meisel A; Wagner AD; Borner M
Oncol Res Treat; 2020; 43(5):237-244. PubMed ID: 32146471
[TBL] [Abstract][Full Text] [Related]
17. Trifluridine/tipiracil plus bevacizumab as a first-line treatment for elderly patients with metastatic colorectal cancer (KSCC1602): A multicenter phase II trial.
Oki E; Makiyama A; Miyamoto Y; Kotaka M; Kawanaka H; Miwa K; Kabashima A; Noguchi T; Yuge K; Kashiwada T; Ando K; Shimokawa M; Saeki H; Akagi Y; Baba H; Maehara Y; Mori M
Cancer Med; 2021 Jan; 10(2):454-461. PubMed ID: 33249761
[TBL] [Abstract][Full Text] [Related]
18. A Phase I dose-escalation study of third-line regorafenib with trifluridine/tipiracil in metastatic colorectal cancer.
Moehler M; Michel M; Stein A; Trojan J; Marquardt J; Tintelnot J; Waidmann O; Weinmann A; Woerns MA; Schroeder H; Maenz M; Foerster F
Future Oncol; 2021 Sep; 17(25):3309-3319. PubMed ID: 33993741
[TBL] [Abstract][Full Text] [Related]
19. Codon-specific KRAS mutations predict survival benefit of trifluridine/tipiracil in metastatic colorectal cancer.
van de Haar J; Ma X; Ooft SN; van der Helm PW; Hoes LR; Mainardi S; Pinato DJ; Sun K; Salvatore L; Tortora G; Zurlo IV; Leo S; Giampieri R; Berardi R; Gelsomino F; Merz V; Mazzuca F; Antonuzzo L; Rosati G; Stavraka C; Ross P; Rodriquenz MG; Pavarana M; Messina C; Iveson T; Zoratto F; Thomas A; Fenocchio E; Ratti M; Depetris I; Cergnul M; Morelli C; Libertini M; Parisi A; De Tursi M; Zanaletti N; Garrone O; Graham J; Longarini R; Gobba SM; Petrillo A; Tamburini E; La Verde N; Petrelli F; Ricci V; Wessels LFA; Ghidini M; Cortellini A; Voest EE; Valeri N
Nat Med; 2023 Mar; 29(3):605-614. PubMed ID: 36864254
[TBL] [Abstract][Full Text] [Related]
20. External Validation of the Colon Life Nomogram for Predicting 12-Week Mortality in Dutch Metastatic Colorectal Cancer Patients Treated with Trifluridine/Tipiracil in Daily Practice.
Hamers PAH; Wensink GE; van Smeden M; Vink GR; Smabers LP; Lunenberg RA; Laclé MM; Koopman M; May AM; Roodhart JML
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
